9II9

Crystal structure of SARS-CoV-2 neutralizing antibody K4-66

9II9 の概要

• エントリーDOI: 10.2210/pdb9ii9/pdb
• 分子名称: antigen-binding fragments (Fabs) (2 entities in total)
• 機能のキーワード: antigen-binding fragments (fabs), immune system
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 93043.53

構造登録者

Kimura, T.K.,Hashiguchi, T. (登録日: 2024-06-19, 公開日: 2024-11-06, 最終更新日: 2024-11-13)

主引用文献

Kuwata, T.,Kaku, Y.,Biswas, S.,Matsumoto, K.,Shimizu, M.,Kawanami, Y.,Uraki, R.,Okazaki, K.,Minami, R.,Nagasaki, Y.,Nagashima, M.,Yoshida, I.,Sadamasu, K.,Yoshimura, K.,Ito, M.,Kiso, M.,Yamayoshi, S.,Imai, M.,Ikeda, T.,Sato, K.,Toyoda, M.,Ueno, T.,Inoue, T.,Tanaka, Y.,Kimura, K.T.,Hashiguchi, T.,Sugita, Y.,Noda, T.,Morioka, H.,Kawaoka, Y.,Matsushita, S.
Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.
Ebiomedicine, 110:105439-105439, 2024

PubMed Abstract: Emergence of SARS-CoV-2 variants that escape neutralising antibodies hampers the development of vaccines and therapeutic antibodies against SARS-CoV-2. IGHV3-53/3-66-derived public antibodies, which are generally specific to the prototype virus and are frequently induced in infected or vaccinated individuals, show minimal affinity maturation and high potency against prototype SARS-CoV-2.

PubMed: 39488016
DOI: 10.1016/j.ebiom.2024.105439

実験手法

X-RAY DIFFRACTION (2.9 Å)